PURPOSE: Early detection and management of symptoms in patients with cancer improves outcomes. However, the optimal approach to symptom monitoring and management is unknown. InSight Care is a mobile health intervention that captures symptom data and facilitates patient-provider communication to mitigate symptom escalation. PATIENTS AND METHODS: Patients initiating antineoplastic treatment at a Memorial Sloan Kettering regional location were eligible. Technology supporting the program included the following: a predictive model that identified patient risk for a potentially preventable acute care visit; a secure patient portal enabling communication, televisits, and daily delivery of patient symptom assessments; alerts for concerning symptoms; and a symptom-trending application. The main outcomes of the pilot were feasibility and acceptability evaluated through enrollment and response rates and symptom alerts, and perceived value evaluated on the basis of qualitative patient and provider interviews. RESULTS: The pilot program enrolled 100 high-risk patients with solid tumors and lymphoma (29% of new treatment starts v goal of 25%). Over 6 months of follow-up, the daily symptom assessment response rate was 56% (the goal was 50%), and 93% of patients generated a severe symptom alert. Patients and providers perceived value in the program, and archetypes were developed for program improvement. Enrolled patients were less likely to use acute care than were other high-risk patients. CONCLUSION: InSight Care was feasible and holds the potential to improve patient care and decrease facility-based care. Future work should focus on optimizing the cadence of patient assessments, the workforce supporting remote symptom management, and the return of symptom data to patients and clinical teams.
PURPOSE: Early detection and management of symptoms in patients with cancer improves outcomes. However, the optimal approach to symptom monitoring and management is unknown. InSight Care is a mobile health intervention that captures symptom data and facilitates patient-provider communication to mitigate symptom escalation. PATIENTS AND METHODS: Patients initiating antineoplastic treatment at a Memorial Sloan Kettering regional location were eligible. Technology supporting the program included the following: a predictive model that identified patient risk for a potentially preventable acute care visit; a secure patient portal enabling communication, televisits, and daily delivery of patient symptom assessments; alerts for concerning symptoms; and a symptom-trending application. The main outcomes of the pilot were feasibility and acceptability evaluated through enrollment and response rates and symptom alerts, and perceived value evaluated on the basis of qualitative patient and provider interviews. RESULTS: The pilot program enrolled 100 high-risk patients with solid tumors and lymphoma (29% of new treatment starts v goal of 25%). Over 6 months of follow-up, the daily symptom assessment response rate was 56% (the goal was 50%), and 93% of patients generated a severe symptom alert. Patients and providers perceived value in the program, and archetypes were developed for program improvement. Enrolled patients were less likely to use acute care than were other high-risk patients. CONCLUSION: InSight Care was feasible and holds the potential to improve patient care and decrease facility-based care. Future work should focus on optimizing the cadence of patient assessments, the workforce supporting remote symptom management, and the return of symptom data to patients and clinical teams.
Authors: Gabrielle B Rocque; Edward E Partridge; Maria Pisu; Michelle Y Martin; Wendy Demark-Wahnefried; Aras Acemgil; Kelly Kenzik; Elizabeth A Kvale; Karen Meneses; Xuelin Li; Yufeng Li; Karina I Halilova; Bradford E Jackson; Carol Chambless; Nedra Lisovicz; Mona Fouad; Richard A Taylor Journal: J Oncol Pract Date: 2016-05-10 Impact factor: 3.840
Authors: Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag Journal: J Natl Cancer Inst Date: 2014-09-29 Impact factor: 13.506
Authors: Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag Journal: JAMA Date: 2017-07-11 Impact factor: 56.272
Authors: Bobby Daly; Dmitriy Gorenshteyn; Kevin J Nicholas; Alice Zervoudakis; Stefania Sokolowski; Claire E Perry; Lior Gazit; Abigail Baldwin Medsker; Rori Salvaggio; Lynn Adams; Han Xiao; Yeneat O Chiu; Lauren L Katzen; Margarita Rozenshteyn; Diane L Reidy-Lagunes; Brett A Simon; Wendy Perchick; Isaac Wagner Journal: JCO Clin Cancer Inform Date: 2020-03
Authors: Gabrielle B Rocque; Maria Pisu; Bradford E Jackson; Elizabeth A Kvale; Wendy Demark-Wahnefried; Michelle Y Martin; Karen Meneses; Yufeng Li; Richard A Taylor; Aras Acemgil; Courtney P Williams; Nedra Lisovicz; Mona Fouad; Kelly M Kenzik; Edward E Partridge Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Kathi H Mooney; Susan L Beck; Bob Wong; William Dunson; Debra Wujcik; Meagan Whisenant; Gary Donaldson Journal: Cancer Med Date: 2017-01-30 Impact factor: 4.452
Authors: Cara Stabile; Larissa K Temple; Jessica S Ancker; Ethan Basch; Jeanne Carter; Magen Miranda; Daniel Stein; Peter D Stetson; Andrew Vickers; Brett A Simon; Andrea L Pusic Journal: BMJ Open Date: 2019-09-17 Impact factor: 2.692
Authors: Bob T Li; Bobby Daly; Mary Gospodarowicz; Monica M Bertagnolli; Otis W Brawley; Bruce A Chabner; Lola Fashoyin-Aje; R Angelo de Claro; Elizabeth Franklin; Jennifer Mills; Jeff Legos; Karen Kaucic; Mark Li; Lydia The; Tina Hou; Ting-Hui Wu; Bjorn Albrecht; Yi Shao; Justin Finnegan; Jing Qian; Javad Shahidi; Eduard Gasal; Craig Tendler; Geoffrey Kim; James Yan; Phuong Khanh Morrow; Charles S Fuchs; Lianshan Zhang; Robert LaCaze; Stefan Oelrich; Martin J Murphy; Richard Pazdur; Kevin Rudd; Yi-Long Wu Journal: Nat Med Date: 2022-04 Impact factor: 87.241
Authors: Bobby Daly; Tara S Lauria; Jessie C Holland; Jericho Garcia; Jibran Majeed; Chasity B Walters; Melissa Zablocki; Kimberly Chow; Olga Strachna; Caitlin E Giles; Meghan F Kelly; Ashley Housen; Maryanne Canavan; Nina M Maresca; Ray Baser; Rori Salvaggio; Mark E Robson; Diane L Reidy-Lagunes Journal: JCO Oncol Pract Date: 2021-06-04
Authors: Anaeze C Offodile; Sandra R DiBrito; Janice P Finder; Sanjay Shete; Sanchita Jain; Domenica A Delgado; Christopher J Miller; Elenita Davidson; Michael J Overman; Susan K Peterson Journal: BMJ Open Date: 2022-04-05 Impact factor: 2.692
Authors: Kaitlyn Lapen; Christopher Sabol; Amy L Tin; Kathleen Lynch; Alyse Kassa; Xiaolin Mabli; John Ford; Elaine Cha; Michael B Bernstein; Lior Z Braunstein; Oren Cahlon; Bobby M Daly; Kiri Sandler; Susan A McCloskey; Andrew J Vickers; Atif J Khan; Erin F Gillespie Journal: Int J Radiat Oncol Biol Phys Date: 2021-07-24 Impact factor: 7.038